Icahn’s $2 Billion Man Starts Fund as Activists Shun Biotech
This article is for subscribers only.
Alex Denner knows how to spot biotechnology companies with promising drugs and make sure investments pay off.
Working as Carl Icahn’s top health-care investing executive for the past five years, Denner has targeted at least six drugmakers from ImClone Systems Inc. to Biogen Idec Inc., prompting sales of three. He’s generated about $2 billion in profit for Icahn, said a person familiar with his record who declined to be identified because the matter is private.